Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
LONG-ACTING REPEATABLE BROMOCRIPTINE IN THE TREATMENT OF PATIENTS WITH MICROPROLACTINOMA INTOLERANT OR RESISTANT TO ORAL DOPAMINERGICS
Autore:
ESPINOS JJ; RODRIGUEZESPINOSA J; WEBB SM; CALAFALSINA J;
Indirizzi:
UNIV AUTONOMA BARCELONA,HOSP SANTA CRUZ & SAN PABLO,DEPT OBSTET & GYNECOL E-08025 BARCELONA SPAIN UNIV AUTONOMA BARCELONA,HOSP SANTA CRUZ & SAN PABLO,DEPT OBSTET & GYNECOL E-08025 BARCELONA SPAIN
Titolo Testata:
Fertility and sterility
fascicolo: 5, volume: 62, anno: 1994,
pagine: 926 - 931
SICI:
0015-0282(1994)62:5<926:LRBITT>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
DEPOT BROMOCRIPTINE; PROLACTINOMAS; PREGNANCY;
Keywords:
LONG ACTING BROMOCRIPTINE; MICROPROLACTINOMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
19
Recensione:
Indirizzi per estratti:
Citazione:
J.J. Espinos et al., "LONG-ACTING REPEATABLE BROMOCRIPTINE IN THE TREATMENT OF PATIENTS WITH MICROPROLACTINOMA INTOLERANT OR RESISTANT TO ORAL DOPAMINERGICS", Fertility and sterility, 62(5), 1994, pp. 926-931

Abstract

Objective: To study the efficacy of long-acting repeatable bromocriptine in supressing abnormal PRL secretion in microprolactinoma patients. To assess the incidence and nature of side effects induced by the product. Design: Longitudinal, open label, noncontrolled. Setting: Humanhyperprolactinemic volunteers in an academic clinical research environment. Patients: Ten patients with radiologically proven microademonasresistant or intolerant to oral bromocriptine were included. Interventions: The patients were treated with 50 to 150 mg of long-acting bromocriptine monthly during 6 months. Main Outcome Measure: The serum PRLconcentrations and the side-effects were assessed before and after each new injection. Results: Serum PRL levels decreased during the firstcycle to normal values in four patients. At the end of the study the PRL levels were normalized in five cases and were only slightly increased in three. One patient was resistant to the treatment. Two among four infertile women became pregnant. In nine patients the accompanying symptoms disappeared after the 2nd month. Adverse events were mild or moderate and circumscribed to the Ist month of treatment. Conclusion: The long-acting bromocriptine is both effective and well tolerated andis a good alternative to the oral approach in the management of microprolactinoma patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 01:24:44